期刊文献+

广泛性焦虑障碍的药物治疗进展 被引量:8

Advances in drug treatment of generalized anxiety disorder
下载PDF
导出
摘要 广泛性焦虑障碍简称广泛焦虑症,是神经精神科的常见病与多发病.GAD发病机制复杂,涉及遗传、生化和心理等方面.多数患者因伴有呼吸、神经、消化、循环及泌尿系统症状而常被漏诊误诊,因此延误了治疗的最佳时机.口服药物是该病的首选治疗方案.本研究简述了GAD的药物治疗现状,目的在于提高临床医师用药的准确性. GAD( referred to as extensive anxiety disorder) is a common and frequently-occurring disease in neuropsychiatry. The pathogenesis of GAD is complex,involving genetic,biochemical and psychological factors and so on. Many patients are often misdiagnosed or missing diagnosis because of respiratory,nervous,digestive,circulatory and urinary symptoms at the same time,and missing the best treatment opportunities. The first-line reference treatment for GAD is oral drug. The current status of medication in GAD is reviewed in this paper with a view to improve the accuracy of drug use for clinicians.
出处 《转化医学电子杂志》 2016年第3期51-54,共4页 E-Journal of Translational Medicine
关键词 广泛性焦虑障碍(GAD) SNRIs SSRIS 普瑞巴林 阿戈美拉汀 generalized anxiety disorder SNRIs SSRIs pregabalin agomelatine
  • 相关文献

参考文献37

  • 1Stein MB, Sareen J. CLINICAL PRACTICE. Generalized Anxiety Disorder[J]. N Engl J Meal,2015,373 ( 21 ) :2059-2068.
  • 2吴文源,黄继忠,司天梅,许秀峰,梅其一,季建林,李惠春,张宁,陆峥,施慎逊,周东丰,江开达,赵靖平,李凌江,贾福军,王刚,刘铁榜,张明园.文拉法辛缓释剂临床应用专家指导建议[J].中国心理卫生杂志,2013,27(7):550-560. 被引量:60
  • 3Blier P, Saint-Andr E, Hhert C, et al. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers [J]. Int J Neuropsychopharmacol, 2007,10 ( 1 ) :41-50.
  • 4Rickels K, Etemad B, Khalid-Khan S, et al. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release [J]. Arch Gen Psychiatry, 2010, 67(12) : 1274-1281.
  • 5Steen NE, Aas M, Simonsen C, et al. Serum level of venlafaxine is associated with better memory in psychotic disorders [J]. Schizophr Res ,2015,169( 1-3 ) :386-392.
  • 6Selvaraj V, Gunasekar P, Kumar S, et al. Urinary Incontinence due to Overactive Detrusor Muscle: A Rare Side Effect of Venlafaxine[J]. Case Rep Urol,2015:690931.
  • 7Zhang Y, Huang G, Yang S, et al. Duloxetine in treating general- ized anxiety disorder in adults: A meta-analysis of published randomized, double-blind, placebo-controlled trials [J]. Asia Pac Psychiatry.2015 Aug 3.
  • 8刘海林,张思思,吴齐红,刘颖菊.度洛西汀治疗广泛性焦虑障碍疗效和安全性的Meta分析[J].中国药房,2015,26(12):1668-1671. 被引量:4
  • 9Baldwin DS, Polkinghom C. Evidence-based pharmacotherapy of Generalized Anxiety Disorder [J]. Int J Neumpsychopharmacol, 2005,8(2) :293-302.
  • 10Tang SW, Helmeste D. Paroxetine [J]. Expert Opin Pharmacother. 2008,9(5) :787-794.

二级参考文献134

  • 1王玉伟,杨丽芹,孙静,邵长春.西酞普兰与氟西汀治疗抑郁症对照研究[J].临床精神医学杂志,2004,14(4):225-226. 被引量:69
  • 2李焕德.抗抑郁新药顽发克星[J].国外医学(精神病学分册),1995,22(3):165-169. 被引量:45
  • 3于君,郝增平,王培磊.万拉法新联合阿普唑仑治疗伴焦虑症状抑郁症对照研究[J].临床心身疾病杂志,2006,12(1):21-22. 被引量:10
  • 4司天梅,舒良,吉中孚,李惠春,陶明,唐永怡,李晓光,季建林,史以玉,王崇顺,梅其一,欧红霞,翁正,王铭,端义扬,秦晓霞,金雪光.文拉法辛缓释剂治疗抑郁症的开放性研究[J].中华精神科杂志,2006,39(2):85-89. 被引量:38
  • 5江开达,苏晖,徐一峰,李飞,刘晓华,刘义兰,潘桂花.文拉法辛缓释剂和氟西汀治疗首发抑郁症的对照研究[J].上海精神医学,2007,19(1):15-18. 被引量:7
  • 6长田洋文 五岛雄一郎 铃木仁一 等.以循环系统心身疾病为对象的tandospirone(SM-3997)双盲对照临床试验--安慰剂对照,剂量对照,Ⅱ期临床晚期试验[J].基础和临床,1992,26:4311-4350.
  • 7村崎光邦 森温理 远骊俊吉 等.新型精神药物tandospirone(SM-3997)对各种神经症的疗效评价--与安定对照的Ⅲ期临床试验[J].临床评价,1992,20:295-329.
  • 8兼本成斌 五岛雄一郎 铃木仁一 等.新型精神药物SM-3997(tandospirone)的临床评价--以循环系统心身疾病为对象[J].基础和临床,1992,26:4227-4238.
  • 9木村政资 坂田利家 中川哲也 等.新型精神药物SM-3997(tandospirone)的临床评价--以心身疾病、抑郁症及神经症为对象的适应症及最佳剂量研究[J].基础和临床,1992,26:4239-4251.
  • 10清水宏志.Tandospironed的药理作用与5-HT1A的关系[J].基础和临床,1992,26:1697-1702.

共引文献130

同被引文献110

引证文献8

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部